NEW YORK, March 14, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins.

Alison Kosik delivers the pre-market update on March 14th

• Investors welcomed a cooler-than-expected Producer Price Index reading for the month of February as tariff talk continues out of Washington D.C.
• Attention shifts to the Federal Reserve decisions coming next week as inflation data suggests the rate of inflation growth could be slowing.
• S&P 500 looks to rebound after ending yesterday in correction territory, which is a decline of at least 10% from a recent high.

Watch NYSE TV Live every weekday 9:00-10:00am ET 

Video – https://mma.prnewswire.com/media/2641945/NYSE_March_14_2025_Market_Update.mp4
Logo – https://mma.prnewswire.com/media/2581322/New_York_Stock_Exchange_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-pre-market-update-for-march-14-2025-302401916.html

2025 is shaping up to be a milestone year for Curve as it forecasts reaching profitability, expands its product offerings, and prepares to introduce its challenger to Apple Pay and Google Wallet—Curve Pay.

LONDON, March 14, 2025 /PRNewswire/ — Curve, the digital wallet that saves you money, announced today it has secured a £37M investment led by Hanaco Ventures, with participation of existing shareholders such as Fuel Ventures, IDC, Outward VC and Lord Stanley Fink. The funding will support Curve’s ambitious plans for 2025, including industry-first product launches and a series of customer-driven enhancements set to redefine how consumers manage their money in the future. Crucially, this capital injection strengthens Curve’s financial position, accelerating its path to profitability while continuing to innovate and scale.

With regulatory changes forcing behemoths like Apple to open their NFC technology and digital wallet adoption surging across the UK and Europe, combined with banks actively looking to introduce their own Wallet solutions, the market is primed for intense competition in digital wallets. As people seek more options and greater flexibility in how they control their finances, Curve, as the established champion for consumer choice, is developing an offering which benefits both consumers and banks simultaneously. The investment from Hanaco will further enable Curve to capitalize on these market shifts — precipitated by consumer demand for more choice — expanding its market presence and partnerships, strengthening its infrastructure, and enhancing customer experiences.

“This latest investment reflects the confidence in Curve’s vision to redefine the digital wallet space,” said Shachar Bialick, Founder & CEO of Curve. “The Wallet Wars are here, and the only available solutions for customers to date are simple wallets which do nothing more than let you pay with your card. Curve is the only wallet that adds superpowers to your money; avoid Fx fees from any linked card, split old purchases into installments, earn cashback on top of any card and more. We see issuers looking to enter the market, and networks introducing innovative products such as Visa Flex and MasterCard One Credentials. This investment would allow us to invest further in our customer experience, bring new partnerships, and accelerate our path to profitability.” 

“Curve reimagined the digital wallet delivering a one-of-a-kind financial experience that simplifies and supercharges how you pay and manage your money – all without changing your bank,” said Tomer Jacob at Hanaco. “The Curve team has proven to be resilient and innovative, and we are excited to support Curve as it continues to grow, bringing more choice and flexibility to the digital wallet market, and to its millions of users.”

Curve has consistently delivered a digital wallet designed to provide greater control and flexibility to its growing global customer base of what is currently over six million users. Starting with the Curve Card — the one card to rule them all. While benefits like stacking rewards, real-time spending insights, and avoiding foreign exchange fees, empowers customers to save money and make informed financial decisions, innovations such as Go Back in Time® allow them to retroactively move transactions between cards, and manage their cashflow better, avoid debt etc. 

Curve also offers a number of unique borrowing features and benefits. Curve ReFI enables customers to instantly transfer balances from one card to another, preventing unnecessary interest accrual, late payment fees, and overdrafts. Another recent invention, Curve Flex enables customers to split any past or future purchases into manageable instalments, wherever they shop. Further strengthening its commitment to financial empowerment, Curve has this week partnered with Infact to introduce real-time credit reporting for Curve Flex customers. 

A key milestone for the company will be the upcoming launch of Curve Pay, a digital wallet alternative for Android and iOS users. 

About Curve

Curve is a pioneering digital wallet that goes beyond simply storing your cards digitally. Unlike other digital wallets, Curve actively works to save you money and enhance every payment you make. Through its cutting-edge wallet technology, Curve will help you avoid hidden foreign transaction fees from any linked card, allows you to switch payment cards even after purchase, and lets you earn rewards on top of your existing card benefits.

Advertisement

The Curve Wallet sits at the heart of this technology, bringing all your cards and other payment sources into one secure platform while adding unique money-saving features. Whether you’re shopping online, in-store, or abroad, Curve gets the most value for your money. Authorised and regulated in the UK, EEA, and US, Curve has amassed more than 6 million customers globally, and processes billions in payments annually while continuing to innovate in digital finance.

View original content:https://www.prnewswire.co.uk/news-releases/curve-secures-37m-investment-led-by-hanaco-ventures-as-the-company-approaches-profitability-and-prepares-to-launch-curve-pay-in-2025-302401910.html

WOBURN, Mass., March 14, 2025 /PRNewswire/ — Azurity Pharmaceuticals (“Azurity”) announced today the successful completion of its acquisition of Covis Group S.à r.l. (“Covis”) from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity.     

This strategic acquisition reinforces Azurity’s leadership in branded pharmaceuticals, harnessing the complementary strengths of both companies across multiple complex dosage forms and therapeutic areas. By combining expertise and resources, Azurity strengthens its ability to deliver medicines to overlooked patients on a global scale.

Strategic Benefits of the Acquisition:

• Expanded Therapeutic Portfolio – The integration of Covis’ product portfolio and pipeline enhances Azurity’s offerings across ten complex dosage forms and nine key therapeutic areas, including cardiovascular, respiratory, central nervous system, endocrinology, gastrointestinal, hematology, immunology, anti-infectives, and oncology.
• Global Footprint – The acquisition strengthens Azurity’s global footprint, expanding its commercial presence to over 50 countries and enabling greater patient accessibility to life-changing treatments. Azurity and its subsidiaries will employ more than 800 colleagues across North America, Europe and Asia. 
• Key Biopharma Partner of Choice – The combined company is positioned to be a key partner for global life sciences companies looking to develop and commercialize their products, providing partners access to its deep development capabilities and global commercial infrastructure. 
• Accelerated Innovation – By combining expertise and resources, Azurity is positioned to advance innovative treatments furthering Azurity’s mission to serve overlooked patients using a unique and accelerated development process – enabling scale and velocity.
• Next-Gen Commercial Model – The integrated company portfolio will benefit from Azurity’s highly efficient and effective commercial model, combining data, analytics, and AI-driven digital capabilities to drive stakeholder engagement using an optimized omnichannel marketing approach.

“We are excited to welcome Covis Pharma to Azurity,” said Ronald Scarboro, CEO of Azurity. “The efforts of colleagues at both companies, their devotion to overlooked patients, and our culture of execution have brought us together to build this unique, highly differentiated pharmaceutical company. I look forward to all that we will accomplish as we grow globally and embrace new opportunities, driven by our purpose.”

“I am delighted that Azurity recognized the accomplishments and potential of Covis, and am thankful for the tireless efforts of Covis colleagues in support of patients that benefit from the company’s products,” said Rajiv De Silva, Chairman of the Board of Covis. “I am confident that the two companies will be able to untap each other’s highly complementary capabilities to accelerate development and commercialization of necessary medicines to underserved patients.”

“QHP Capital is proud to support Azurity in this acquisition, which aligns with our commitment to investing in life sciences and healthcare innovations,” said Jeff Edwards, Partner at QHP Capital, the majority owner of Azurity. “It has been our privilege to support and enable Azurity from a small, limited product, US-only company at the start of our investment in 2018 to the global, large, diversified portfolio, high-growth company it is today. We are committed to further enabling Azurity for the significant growth its team is well positioned to execute.”

Goldman Sachs served as financial advisor and Eversheds Sutherland and White & Case served as legal advisors to Azurity. Guggenheim Securities served as financial advisor to Covis and Reed Smith and A&O Shearman served as legal advisors to Covis.     

About Azurity Pharmaceuticals:
Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 30+ marketed brands spanning ten dosage forms and nine key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. For more information, visit www.azurity.com.

About QHP Capital: 
QHP Capital is an investor in technology and services companies in the life sciences, medical technology, and healthcare sectors. QHP has built an investment platform to provide strategic capital and industry expertise in partnership with strong management teams. The investment team consists of seasoned investment and operational professionals with significant investment experience and deep life science, medical technology, and healthcare expertise. QHP benefits from an extensive network of industry experts that assist in identifying, analyzing, and growing QHP’s portfolio companies. For more information, please visit www.qhpcapital.com.

Disclosure notice: Azurity and QHP undertake no obligation to update or revise any forward-looking statements contained in this release as a result of new information, future events, or evolving circumstances.  

Logo – https://mma.prnewswire.com/media/1435351/Azurity_r_rgb_Logo.jpg

Advertisement

View original content:https://www.prnewswire.co.uk/news-releases/azurity-pharmaceuticals-completes-acquisition-of-covis-pharma-302401906.html